Annual CFF
$130.18 M
+$36.19 M+38.50%
31 December 2023
Summary:
Tarsus Pharmaceuticals annual cash flow from financing activities is currently $130.18 million, with the most recent change of +$36.19 million (+38.50%) on 31 December 2023. During the last 3 years, it has fallen by -$1.59 million (-1.21%). TARS annual CFF is now -1.21% below its all-time high of $131.77 million, reached on 31 December 2020.TARS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$639.00 K
-$41.68 M-98.49%
30 September 2024
Summary:
Tarsus Pharmaceuticals quarterly cash flow from financing activities is currently $639.00 thousand, with the most recent change of -$41.68 million (-98.49%) on 30 September 2024. Over the past year, it has dropped by -$104.25 million (-99.39%). TARS quarterly CFF is now -99.41% below its all-time high of $108.77 million, reached on 31 March 2024.TARS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$171.49 M
-$104.25 M-37.81%
30 September 2024
Summary:
Tarsus Pharmaceuticals TTM cash flow from financing activities is currently $171.49 million, with the most recent change of -$104.25 million (-37.81%) on 30 September 2024. Over the past year, it has increased by +$60.81 million (+54.94%). TARS TTM CFF is now -37.81% below its all-time high of $275.74 million, reached on 30 June 2024.TARS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TARS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +38.5% | -99.4% | +54.9% |
| 3 y3 years | -1.2% | +752.0% | +86.7% |
| 5 y5 years | +3552.5% | - | - |
TARS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1.2% | >+9999.0% | -99.4% | +569.9% | -37.8% | >+9999.0% |
| 5 y | 5 years | -1.2% | >+9999.0% | -99.4% | +569.9% | -37.8% | >+9999.0% |
| alltime | all time | -1.2% | >+9999.0% | -99.4% | +569.9% | -37.8% | >+9999.0% |
Tarsus Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $639.00 K(-98.5%) | $171.49 M(-37.8%) |
| June 2024 | - | $42.32 M(-61.1%) | $275.74 M(+17.9%) |
| Mar 2024 | - | $108.77 M(+450.5%) | $233.93 M(+79.7%) |
| Dec 2023 | $130.18 M(+38.5%) | $19.76 M(-81.2%) | $130.18 M(+17.6%) |
| Sept 2023 | - | $104.89 M(>+9900.0%) | $110.68 M(+1858.6%) |
| June 2023 | - | $510.00 K(-89.8%) | $5.65 M(-92.9%) |
| Mar 2023 | - | $5.01 M(+1798.9%) | $79.88 M(-15.0%) |
| Dec 2022 | $93.99 M | $264.00 K(-294.1%) | $93.99 M(+0.4%) |
| Sept 2022 | - | -$136.00 K(-100.2%) | $93.65 M(-0.2%) |
| June 2022 | - | $74.73 M(+290.8%) | $93.86 M(+390.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $19.13 M(<-9900.0%) | $19.13 M(>+9900.0%) |
| Dec 2021 | $21.00 K(-100.0%) | -$74.00 K(-198.7%) | $21.00 K(-100.0%) |
| Sept 2021 | - | $75.00 K(+7400.0%) | $91.86 M(-30.2%) |
| June 2021 | - | $1000.00(-94.7%) | $131.68 M(-0.1%) |
| Mar 2021 | - | $19.00 K(-100.0%) | $131.82 M(+0.0%) |
| Dec 2020 | $131.77 M(+121.7%) | $91.76 M(+130.0%) | $131.77 M(+229.4%) |
| Sept 2020 | - | $39.90 M(>+9900.0%) | $40.01 M(>+9900.0%) |
| June 2020 | - | $134.00 K(-596.3%) | $107.00 K(-496.3%) |
| Mar 2020 | - | -$27.00 K | -$27.00 K |
| Dec 2019 | $59.45 M(+1567.9%) | - | - |
| Dec 2018 | $3.56 M | - | - |
FAQ
- What is Tarsus Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals annual CFF year-on-year change?
- What is Tarsus Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals quarterly CFF year-on-year change?
- What is Tarsus Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals TTM CFF year-on-year change?
What is Tarsus Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of TARS is $130.18 M
What is the all time high annual CFF for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high annual cash flow from financing activities is $131.77 M
What is Tarsus Pharmaceuticals annual CFF year-on-year change?
Over the past year, TARS annual cash flow from financing activities has changed by +$36.19 M (+38.50%)
What is Tarsus Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of TARS is $639.00 K
What is the all time high quarterly CFF for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high quarterly cash flow from financing activities is $108.77 M
What is Tarsus Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, TARS quarterly cash flow from financing activities has changed by -$104.25 M (-99.39%)
What is Tarsus Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of TARS is $171.49 M
What is the all time high TTM CFF for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high TTM cash flow from financing activities is $275.74 M
What is Tarsus Pharmaceuticals TTM CFF year-on-year change?
Over the past year, TARS TTM cash flow from financing activities has changed by +$60.81 M (+54.94%)